Last reviewed · How we verify
Routine Treatment
At a glance
| Generic name | Routine Treatment |
|---|---|
| Also known as | Treatment |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Shared Decision-Making Decision Aid for Newly Diagnosed Breast Cancer : A Multi-Center Randomized Controlled Trial (NA)
- NCI COVID-19 in Cancer Patients, NCCAPS Study
- Induction of Labor by Cervical Ripening and Transcutaneous Electrical Nerve Stimulation (TENS) (NA)
- Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy (NA)
- Ablation Versus Medical Management of Atrial Fibrillation in HFpEF (NA)
- A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Routine Treatment CI brief — competitive landscape report
- Routine Treatment updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI